Rivaroxaban for prevention and treatment of venous thromboembolism

被引：9
|
作者：
Chan, Noel C. [1 ,2 ]
Weitz, Jeffrey, I [1 ,2 ]
机构：
[1] McMaster Univ, Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada
[2] McMaster Univ, Dept Med, Hamilton, ON, Canada
来源：
FUTURE CARDIOLOGY | 2019年 / 15卷 / 02期
关键词：
nonvitamin K oral antagonist; rivaroxaban; venous thromboembolism; FACTOR-XA INHIBITOR; DIRECT ORAL ANTICOAGULANTS; DEEP-VEIN THROMBOSIS; TOTAL HIP; ORTHOPEDIC-SURGERY; EXTENDED TREATMENT; KNEE REPLACEMENT; REAL-WORLD; ENOXAPARIN; THROMBOPROPHYLAXIS;
D O I：
10.2217/fca-2018-0076
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Until recently, heparins and vitamin K antagonists (VKAs) were the cornerstones for prevention and treatment of venous thromboembolism (VTE). This situation changed with the introduction of the direct oral anticoagulants, which are now replacing low-molecular-weight heparin for thromboprophylaxis after elective hip or knee arthroplasty and VKAs for VTE treatment. Rivaroxaban, an oral factor Xa inhibitor, was the first direct oral anticoagulant licensed for VTE prevention and treatment. This paper provides the rationale for factor Xa as a target for anticoagulants, describes the development of rivaroxaban, reviews its pharmacological profile, discusses the clinical trials with rivaroxaban for VTE prevention and treatment and highlights areas of uncertainty.
引用
收藏
页码：63 / 77
页数：15
相关论文
共 50 条
  • [21] Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal
    Stevenson, M.
    Scope, A.
    Holmes, M.
    Rees, A.
    Kaltenthaler, E.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 43 - 48
  • [22] Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery
    Huang, Qiang
    Xing, Shu-xing
    Zeng, Yi
    Si, Hai-bo
    Zhou, Zong-ke
    Shen, Bin
    ORTHOPAEDIC SURGERY, 2019, 11 (05) : 886 - 894
  • [23] Rivaroxaban for the prevention of venous thromboembolism after radiofrequency ablation of saphenous veins concomitant with miniphlebectomy, sclerotherapy, or no treatment of varicose tributaries
    Murzina, Elena
    Lobastov, Kirill
    Laberko, Leonid
    Dvornikov, Anton
    Popov, Ivan
    PHLEBOLOGY, 2021, 36 (09) : 741 - 751
  • [24] Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
    Weitz, J. I.
    Lensing, A. W. A.
    Prins, M. H.
    Bauersachs, R.
    Beyer-Westendorf, J.
    Bounameaux, H.
    Brighton, T. A.
    Cohen, A. T.
    Davidson, B. L.
    Decousus, H.
    Freitas, M. C. S.
    Holberg, G.
    Kakkar, A. K.
    Haskell, L.
    van Bellen, B.
    Pap, A. F.
    Berkowitz, S. D.
    Verhamme, P.
    Wells, P. S.
    Prandoni, P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (13) : 1211 - 1222
  • [25] Emerging anticoagulants for venous thromboembolism prevention
    Trujillo, Toby C.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (10) : S17 - S25
  • [26] Drugs for Treatment and Prevention of Venous Thromboembolism
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2022, 64 (1655):
  • [27] Rivaroxaban for venous thromboembolism prevention after total knee arthroplasty: RECORD3 findings
    Ageno, Walter
    EUROPEAN JOURNAL OF ORTHOPAEDIC SURGERY AND TRAUMATOLOGY, 2009, 19 (08) : 529 - 533
  • [28] Rivaroxaban An Oral Direct Factor Xa Inhibitor for the Prevention of Thromboembolism
    Chen, Terry
    Lam, Sum
    CARDIOLOGY IN REVIEW, 2009, 17 (04) : 192 - 197
  • [29] Aspirin for prevention and treatment of venous thromboembolism
    Becattini, Cecilia
    Agnelli, Giancarlo
    BLOOD REVIEWS, 2014, 28 (03) : 103 - 108
  • [30] Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight
    Perales, Isaac J.
    San Agustin, Kimberly
    DeAngelo, Jessica
    Campbell, Ashley M.
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (04) : 344 - 350
12345